Inc. · Aug 2025
Inc. profiles how Aakash and Manan Shah used Reddit and YouTube to grow Wyndly into a multimillion-dollar business, saying the company doubled sales in 2024 and surpassed $1M in its first year.
Company research
Public company, workplace, funding, and market signals
Updated Jul 29, 2026
Overview
Wyndly is a doctor-founded telehealth allergy practice that offers at-home testing and personalized sublingual immunotherapy (SLIT) for environmental allergies, using a direct-to-patient, virtual care model.
Primary product
At-home allergy testing plus personalized sublingual immunotherapy treatment plans
Founded
2020
Headquarters
New York City, United States
Team size
11-50
Industry
Wellness and Fitness Services
Sub-industry
Digital health / allergy telehealth / sublingual immunotherapy
Offices
Lakewood, Colorado, United States
New York, New York, United States
Denver, Colorado, United States
Business model
Direct-to-consumer telehealth
Direct-pay subscription
B2B practice enablement
Funding
Stage
Seed
Total raised
$2M
Latest round
Seed · Feb 2023
Latest amount
$2M
Feb 2023 · Y Combinator, Goodwater Capital, Civilization Ventures, Sweater Ventures, Kevin Mahaffey
Feb 2021 · Y Combinator
People & investors
Leadership
Founder, Chief Executive Officer
Founder, Chief Medical Officer
Kent Northcote, MD
Physician
John Moustoukas, MD
Physician
Bhavesh Patel, MD
Physician
Nick Dahl, DO
Physician
Zara Patel, MD
Medical Advisor
Brian D’Anza, MD
Medical Advisor
Work & culture
Company messaging emphasizes doctor-led, patient-centered care, accessibility, personalization, and a culture built around compassion, focus, courage, and progress.
Benefits
HSA/FSA eligible
Free shipping
24/7 doctor support
90-day money-back guarantee
At-home testing
Virtual consultations
No co-pays for the core model
Product & market
Pricing
Direct-pay subscription with monthly treatment pricing, annual or quarterly billing options, and separate at-home test/consult pricing; treatment is HSA/FSA eligible and not primarily insurance-billed.
Differentiators
- —Physician-founded and ENT-led
- —At-home testing and home-delivered SLIT
- —24/7 doctor access
- —90-day money-back guarantee
- —Can prescribe custom drops and FDA-approved SLIT tablets when appropriate
- —Nationwide U.S. telehealth coverage
Technology
Shopify
Cloudflare
Klaviyo
Klaviyo SMS
Google Analytics
Google Tag Manager
Facebook Pixel
TikTok Pixel
Shop Pay
PayPal Express Checkout
Typeform
Calendly
reCAPTCHA
YouTube
Microsoft Clarity
Adobe Fonts
Customers
U.S. patients with environmental allergies
Patients with pollen, pet dander, dust mite, and mold allergies
Children age 5+ eligible for treatment
Other medical practices using Wyndly's B2B offering
Competitors
Curex
Nectar
Aspire Allergy & Sinus
AllergenIQ
Cleared
Scale & contact
Estimated revenue
USD 1M-10M
Estimated monthly visits
398.6K
Traffic estimate as of Jun 2026
Latest news
Founders Table · Sep 2024
Founder interview on the origin story, direct-to-consumer allergy care model, and Wyndly's growth strategy.
Tech Funding News · Feb 2023
Coverage of Wyndly's $2M round, the investors involved, and the company's allergy-drop telehealth model.
TechCrunch · Feb 2021
Early launch coverage explaining Wyndly's telemedicine-based allergy-drop offering, initial expansion states, and product pricing.
Jobs and careers at Wyndly
0 jobs at Wyndly
No open positions
Check back later for new openings